Buserelin (Suprefact) is a powerful synthetic GnRH agonist driving hormonal control in conditions like prostate cancer and endometriosis. It dramatically reduces hormone levels, paving the way for effective therapeutic interventions, despite its unavailability in the US and Australia.
Mechanism
Buserelin targets GnRH receptors, initially triggering LH and FSH release for a temporary hormone surge--the 'flare' effect. This is quickly followed by receptor downregulation and long-term suppression of gonadal steroid production, leading to sustained decreases in testosterone and estradiol levels, crucial for treating prostate cancer and endometriosis.
Research
Studies confirm buserelin's role in achieving medical castration for prostate cancer, alleviating endometriosis pain, and enhancing IVF success by controlling LH surges. However, long-term monitoring is essential due to potential side effects, including bone density loss and emotional shifts, highlighting the need for individualized assessment.
Synergies
When combined with antiandrogens, buserelin can effectively manage flare risks in prostate cancer or be paired with add-back therapy in endometriosis, mitigating hypoestrogenic effects. Ben IQ analyzes YOUR labs and goals to devise the ideal stacking approach.
Trade-Offs
While offering substantial therapeutic rewards, buserelin may induce hormonal suppression, affecting energy and mood. Keep in mind that these side effects are general considerations; YOUR unique situation calls for careful data evaluation.